CD68 and neoplasm: Intravenous injection of MSCs reduced the presence of CD3+ T lymphocytes (Figure 3(a)), CD4+ T helper cells (Figure 3(b)), CD68+ macrophages (Figure 3(c)), TNF-α-producing (Figure 3(d)), and IL-17-producing cells (Figure 3(e)) in the lungs of LLC1-treated mice 28 days after tumor induction.